2021
Tumor immunology CRISPR screening: present, past, and future
Dong MB, Tang K, Zhou X, Zhou JJ, Chen S. Tumor immunology CRISPR screening: present, past, and future. Trends In Cancer 2021, 8: 210-225. PMID: 34920978, PMCID: PMC8854335, DOI: 10.1016/j.trecan.2021.11.009.Peer-Reviewed Original Research
2017
Diverse Class 2 CRISPR-Cas Effector Proteins for Genome Engineering Applications
Pyzocha NK, Chen S. Diverse Class 2 CRISPR-Cas Effector Proteins for Genome Engineering Applications. ACS Chemical Biology 2017, 13: 347-356. PMID: 29121460, PMCID: PMC6768076, DOI: 10.1021/acschembio.7b00800.Peer-Reviewed Original ResearchConceptsGenome engineering applicationsCRISPR-Cas genome editing technologiesMicrobial adaptive immune systemGenome editing technologyEffector enzymeNucleic acid cleavageEditing technologyUnique propertiesModern molecular biologyEngineering applicationsEffector proteinsMammalian cellsMolecular biologyAdaptive immune systemWide diversityTechnologyEnzymeApplicationsFunctionalityAcid cleavageImmune systemBiologyProteinDNADiversity